The 20-Year Public Health Impact and Direct Cost of Testosterone Deficiency in U.S. Men
- 1 February 2013
- journal article
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 10 (2), 562-569
- https://doi.org/10.1111/j.1743-6109.2012.02944.x
Abstract
Introduction Testosterone deficiency (TD) imposes a substantial public health burden in the U.S. We modeled the costs associated with TD‐related sequelae including cardiovascular disease (CVD), diabetes mellitus (DM), and osteoporosis‐related fractures (ORFs). Aim To quantify the incremental cost burden imposed by TD's cardiometabolic sequelae. Method Incidence, prevalence, and mortality of these conditions were collected for men ages 45–74 from six national databases and large cross‐sectional studies. Relative risk (RR) rates were determined for these sequelae in patients with T < 300 ng/dL. The prevalence of TD was determined for this cohort of men. Main Outcome Measures Adjusted incidence and prevalence were determined. Annual costs for the three TD‐related sequelae were inflated at a real rate of 3% for 20 years. Results Actual and adjusted (normalized for T deficiency) rates of CVD, DM, and ORFs in U.S. men aged 45–74 assuming a TD prevalence of 13.4% were calculated. We determined that, over a 20‐year period, T deficiency is projected to be involved in the development of approximately 1.3 million new cases of CVD, 1.1 million new cases of DM, and over 600,000 ORFs. In year 1, the attributed cost burden of these diseases was approximately $8.4 billion. Over the entire 20‐year period, T deficiency may be directly responsible for approximately $190–$525 billion in inflation‐adjusted U.S. health care expenditures. Conclusion TD may be a significant contributor to adverse public health. Further study is needed to definitively describe the whether TD is a modifiable risk factor for CVD, DM, and ORFs. This may represent an opportunity for nationwide public health initiatives aimed at preventive care. Moskovic DJ, Araujo AB, Lipshultz LI, and Khera M. The 20‐year public health impact and direct cost of testosterone deficiency in U.S. men. J Sex Med **;**:**–**.Keywords
This publication has 40 references indexed in Scilit:
- Testosterone Replacement in Hypogonadal Men With Type 2 Diabetes and/or Metabolic Syndrome (the TIMES2 Study)Diabetes Care, 2011
- Adverse Events Associated with Testosterone AdministrationNew England Journal of Medicine, 2010
- Projected Effect of Dietary Salt Reductions on Future Cardiovascular DiseaseNew England Journal of Medicine, 2010
- Fifty‐ two—Week Treatment With Diet and Exercise Plus Transdermal Testosterone Reverses the Metabolic Syndrome and Improves Glycemic Control in Men With Newly Diagnosed Type 2 Diabetes and Subnormal Plasma TestosteroneJournal of Andrology, 2009
- Economic Costs of Diabetes in the U.S. in 2007Diabetes Care, 2008
- Low Serum Testosterone and Mortality in Older MenJournal of Clinical Endocrinology & Metabolism, 2008
- Incidence and Economic Burden of Osteoporosis-Related Fractures in the United States, 2005–2025Journal of Bone and Mineral Research, 2007
- Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy for Prostate CancerJournal of Clinical Oncology, 2006
- Sex Differences of Endogenous Sex Hormones and Risk of Type 2 DiabetesJAMA, 2006
- Coping with multiple morbidity in a life tableMathematical Population Studies, 1998